K. Rai

The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine

P. Wang, R. Gartenhaus, M. Hoffman, 1996, Journal of Molecular Medicine.

Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.

M. Hoffman, D. Janson, K. Rai, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutator phenotype in a subset of chronic lymphocytic leukemia.

D. Sidransky, P. Wang, R. Gartenhaus, 1996, Blood.

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.

L. Gordon, M. Tallman, T. Kuzel, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hairy Cell Leukemia: Proliferation of a Cell with Phagocytic and B‐Lymphocyte Properties

R. Winchester, H. Kunkel, S. Fu, 1974, Scandinavian journal of immunology.

Cytotoxicity of 2-chlorodeoxadenosine (cladribine, 2-cdA) in combination with other chemotherapy drugs against two lymphoma cell lines.

M. Lesser, M. Hoffman, K. Rai, 1999, Leukemia & lymphoma.

Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

C. Croce, John Calvin Reed, S. Krajewski, 1998, Blood.

Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia

N Gupta, S Kavuru, D Patel, 2002, Leukemia.

Impaired interferon alpha response in hairy cell leukemia is corrected by therapy with 2-chloro-2'-deoxyadenosine: implications for susceptibility to opportunistic infections.

P. Fitzgerald-Bocarsly, F. Siegal, A. Sawitsky, 1994, Leukemia.